These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17099619)

  • 1. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
    Gilbert J; Argiris A
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for head and neck cancer.
    Rhee JC; Khuri FR; Shin DM
    Expert Opin Emerg Drugs; 2004 May; 9(1):91-104. PubMed ID: 15155138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neck.
    Awada A; Ismael G
    Curr Opin Oncol; 2007 May; 19(3):177-9. PubMed ID: 17414633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor directed therapy in head and neck cancer.
    Choong NW; Cohen EE
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review.
    Murdoch D
    Curr Opin Oncol; 2007 May; 19(3):216-21. PubMed ID: 17414639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New advances in targeted therapies for squamous cell carcinoma of the head and neck.
    Machiels JP; Schmitz S
    Anticancer Drugs; 2011 Aug; 22(7):626-33. PubMed ID: 21048493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer.
    Marur S; Forastiere AA
    Curr Opin Oncol; 2010 May; 22(3):206-11. PubMed ID: 20216313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications.
    Langer CJ
    Cancer; 2008 Jun; 112(12):2635-45. PubMed ID: 18442098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating novel agents into the curative treatment of head and neck cancer.
    Haddad R; Allen A; Wirth L; Tishler R; Posner M
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):157-9. PubMed ID: 16445367
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE
    J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy.
    Machiels JP; Schmitz S
    Curr Opin Oncol; 2011 May; 23(3):241-8. PubMed ID: 21358328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
    Panikkar RP; Astsaturov I; Langer CJ
    Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
    Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
    J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head and neck cancer: integrating anti-EGFR treatment with standard therapy.
    Kies MS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S52-9. PubMed ID: 19780246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging molecular targeted therapies in the treatment of head and neck cancer.
    Bozec A; Peyrade F; Fischel JL; Milano G
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.
    Harrington KJ; Kazi R; Bhide SA; Newbold K; Nutting CM
    Indian J Cancer; 2010; 47(3):248-59. PubMed ID: 20587899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeted therapy of head and neck cancer: review and clinical development challenges.
    Le Tourneau C; Faivre S; Siu LL
    Eur J Cancer; 2007 Nov; 43(17):2457-66. PubMed ID: 17904355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapies for squamous cell carcinoma of the head and neck.
    Kurtin SE
    Semin Oncol Nurs; 2009 Aug; 25(3):183-92. PubMed ID: 19635397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.